Childhood bullous pemphigoid: a report of three cases in China

Yang, Baoqi; Wu, Mei; Yan, Xiaoxiao; Bao, Fangfang; Yue, Zhenming; Pei, Zhenhuan; Yu, Man; Zhou, Guangjun; Zhang, Furen

doi:10.1111/ijd.12979

Cited by 4 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BP in children is very rare. The number of reported cases is less than 100 cases ( 101 ). The first-line treatment of BP in children is systemic corticosteroids but children are highly vulnerable to the side effects of systemic corticosteroids, notably infections and growth retardation ( 102 ).…”

Section: Discussionmentioning

confidence: 99%

Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review

Cao

Zhang

2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundBullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease of the skin. First-line treatment of systemic corticosteroids may cause serious adverse events. Rituximab, omalizumab, and dupilumab should be explored as alternative treatment options to improve outcomes.ObjectiveTo systematically review the rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid.MethodsA PubMed, Embase, Web of Science, and Cochrane library search were conducted on March 10, 2022. A total of 75 studies were included using Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.ResultsUse of rituximab (n=122), omalizumab (n=53) and dupilumab (n=36) were reported in 211 patients with BP. Rituximab led to complete remission in 70.5% (n=86/122) and partial remission in 23.8% (n=29/122) of patients within 5.7 months, with a recurrence rate of 20.5% (n=25/122). 9.0% (n=11/122) of patients died and infection (6.6%, n=8/122) was the most common adverse event. Omalizumab led to complete remission in 67.9% (n=36/53) and partial remission in 20.8% (n=11/53) of patients within 6.6 months, with a recurrence rate of 5.7% (n=3/53). 1.9% (n=1/53) of patients died and thrombocytopenia (1.9%, n=1/53) was observed as the most common adverse event. Dupilumab led to complete remission in 66.7% (n=24/36) and partial remission in 19.4% (n=7/36) of patients within 4.5 months of treatment without any reported adverse events, with a recurrence rate of 5.6% (n=2/36).ConclusionsRituximab, omalizumab, and dupilumab have similar clinical benefits for BP patients. However, rituximab resulted in higher recurrence rates, adverse events, and mortality rates.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022316454.

show abstract

Section: Discussionmentioning

confidence: 99%

Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review

Cao

Zhang

2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…However, in the literature, BP has been reported after the first set of vaccinations (tetanus, diphtheria, pertussis, and polio) and hepatitis B vaccine. [12] In addition, a BP case that developed after homeopathy treatment including sulfur, mercury, and Rhus ( Toxicodendron ) had also been reported. [5] The literature also shows that BP may be triggered by infectious factors such as scabies in adult patients.…”

Section: Discussionmentioning

confidence: 99%

“…DIF test of perilesional skin samples commonly indicates linear deposition of IgG and C3 in the basal membrane. [18]…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bullous pemphigoid induced by metamizole in a pediatric patient

Uçmak

İbiloğlu

2018

Indian J Dermatol

View full text Add to dashboard Cite

Bullous pemphigoid (BP) is an autoimmune bullous disease commonly seen in adult population but rarely encountered in the pediatric population. Although the exact etiology of BP remains unclear, various vaccines, infectious agents, and drug use have been blamed in the etiology of BP. Here, we present a 14-year-old patient who developed BP after using metamizole and whose diagnosis was clinically and histopathologically confirmed.

show abstract

“…Mean age at onset of BP was 69 years, ranging from 0 to 97 years without gender bias. Three infant BP patients, who were less than 1 year old and reported as case series previously (Yang et al, 2016), were also included in the study. The study was approved by the Institutional Review Board of Shandong Provincial Institute of Dermatology and Venereology and all the subjects or their parents gave written informed consent.…”

mentioning

confidence: 99%